IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies

The clinical application of conventional peptide drugs, such as the HIV-1 fusion inhibitor enfuvirtide, is limited by their short half-life in vivo. To overcome this limitation, we developed a new strategy to extend the in vivo half-life of a short HIV-1 fusion inhibitory peptide, CP24, by fusing it...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:PLoS Pathog
Main Authors: Bi, Wenwen, Xu, Wei, Cheng, Liang, Xue, Jing, Wang, Qian, Yu, Fei, Xia, Shuai, Wang, Qi, Li, Guangming, Qin, Chuan, Lu, Lu, Su, Lishan, Jiang, Shibo
Formato: Artigo
Idioma:Inglês
Publicado: Public Library of Science 2019
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6894747/
https://ncbi.nlm.nih.gov/pubmed/31805154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.ppat.1008082
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares